4th Annual Biopharmaceutical Research & Development Symposium
Dates: September 7-8, 2017
Registration Deadline and abstract submission: August 21, 2017
UNMC Center for Drug Discovery
Lozier Center for Pharmacy Sciences and Education
2nd Floor (Room 2006)
4040 Emile Street
The need for “personalized medicines” has opened the doors for turning nucleic acids into therapeutics. The possibility of applying genome-editing methods to treat diseases has attracted an enormous amount of scientific, clinical and commercial interest. Translating this potential into reality will require collaboration between scientists working on optimization of genome-editing techniques, gene therapy and drug delivery. With the aim of nurturing this collaboration and student learning objectives, the College of Pharmacy at the University of Nebraska Medical Center (UNMC) is organizing the 4th Annual Biopharmaceutical Research & Development Symposium on September 7-8, 2017. This two-day symposium will include speakers from each of these distinct scientific communities. At this symposium, leaders in the field of genome-editing, drug delivery, polymer chemistry, biophysics, clinicians, bioinformatics and genetics can discuss the pros and cons of genome-editing and their use for precision medicines and bioimaging. Through talks, poster session and panel of discussion, this meeting will help identify the scientific, clinical and regulatory hurdles that remain to be overcome. In addition, two post-doctoral and two pre-doctoral graduates will be selected to give an oral presentation. Pre/Post-doctoral graduates will be encouraged to make poster presentation. This symposium will provide a unique opportunity to the faculty, post-docs, graduate students, women, minorities, and individuals with disabilities of local and national universities to have discussions with scientists from industries on the topics of mutual interest.
Goals and Objectives
This symposium will highlight different facets of developing tools for precision genome-engineering in humans for therapeutic and diagnosis of genetic disorders. Translation of precision medicine-based nanotechnologies from bench research to clinical practice is vital; this symposium aims at facilitating such developments. The following issues related to nucleic acid-based “personalized medicines” will be discussed at this symposium:
- Importance and application of nucleic acids-based genome-engineering and bioimaging.
- Delivery of genome-engineering and site-specific nucleases tools.
- Appropriate disease model to faithfully recap clinical cases.
- Discovery of relevant biomarkers for targeted therapeutic endpoints.
- Effect of oligonucleotide backbone modifications on stability and efficacy.
- Small molecules as miRNA modulator for gene therapy.
- Technical consideration in design and selection of biomaterials for formulation.
- Design of preclinical and clinical studies for evaluation of safety and efficacy.
Who should attend?
Scientists in both academia and industry who desire to learn the current issues and perspectives in the practice of “Genome Editing and Silencing for Precision Medicines” from scientific, industrial and regulatory perspectives.
Reports of original data should include an abstract of no more than 500 words including background, methods, results and conclusions. Figures and illustrations are not allowed. As font, please use Arial, size 11. Abstracts chosen for poster presentation at the symposium must be prepared in advance on a poster board, 8 feet wide by 4 feet high (2.44 x 1.22 meters) (Landscape Orientation).
- Vincent HL Lee, The Chinese University of Hong Kong, Hong Kong
Research breakthroughs in pharmaceutical sciences
- Yoshinobu Takakura, Kyoto University, Japan
Exosome-based nucleic acid drug delivery for cancer immunotherapy
- Kamel Khalili, Temple University School of Medicine, USA
Elimination of HIV-1 DNA by CRISPR Technology in Living Animals
- Jianzhong Du, Tongji University, China
Design of novel biomaterials for drug delivery
- Shengdar Tsai, St. Jude Children's Research Hospital, USA
Defining Genome-wide Activity of CRISPR-Cas Nucleases for Therapeutics
- Daniel Siegwart, University of Texas Southwestern Medical Center, USA
Non-viral CRISPR/Cas gene editing enabled by co-delivery of mRNA and sgRNA inside of synthetic lipid nanoparticles
- Channabasavaiah Gurumurthy, University of Nebraska Medical Center, USA
The CRISPR/Cas9 System and the Latest Trends in Animal Genome Engineering
- Lili Yang, University of California, USA
Stem cell-engineered invariant natural killer T-cells for cancer therapy
- Won Jong Kim, Pohang University of Science and Technology, South Korea
Stimuli-responsive nanomedicine for anticancer therapy
- Rolf Turk, Integrated DNA Technologies, USA
Efficient homology-directed repair using long single-stranded DNA templates
- Carol Szczepaniak, Nebraska Coalition for Ethical Research
The Ethical Issues of CRISPR/Cas9 Technology: Aspiring Towards Perfection or Annihiliation?
- Katherine Pawelczak, VP of Research, NERx Biosciences
Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering using novel inhibitors of the Ku-DNA interaction
- Michael Dixon, President and CEO, UNeMed Corporation, UNMC, USA
Role of Intellectual Property in Drug Discovery and Development
- Andrew Godwin, University of Kansas Medical Center, USA
Exosomes in Precision Medicine: Cancer Detection and Monitoring using Liquid Biopsy Blood Testing
- Timothy J. Miller, President and CEO of Abeona Therapeutics Inc ($ABEO)
Developing next generation gene therapy products for rare disease treatments